Clinical experiment designed to assess clinical efficacy targeting CSVD in human. Primary outcome: Validate Vascular Contributions to Alzheimer Disease and Mixed Pathology
Description
Vascular Contributions to Alzheimer Disease and Mixed Pathology
Background and Rationale
Cerebral small vessel disease (CSVD) represents a critical yet understudied contributor to Alzheimer's disease (AD) pathogenesis and mixed dementia phenotypes. While amyloid and tau pathologies have dominated AD research, accumulating evidence suggests vascular dysfunction may precede and accelerate neurodegeneration. This comprehensive clinical study aims to validate the mechanistic role of CSVD in AD progression and characterize mixed pathology presentations combining vascular and neurodegenerative features. The study employs a longitudinal cohort design recruiting participants across the cognitive spectrum, from cognitively normal elderly to mild cognitive impairment and dementia patients. Advanced neuroimaging will quantify CSVD burden using white matter hyperintensities, lacunes, microbleeds, and perivascular spaces on high-resolution MRI. Simultaneous assessment of AD biomarkers through cerebrospinal fluid analysis and PET imaging will enable correlation of vascular pathology with amyloid and tau accumulation....
Vascular Contributions to Alzheimer Disease and Mixed Pathology
Background and Rationale
Cerebral small vessel disease (CSVD) represents a critical yet understudied contributor to Alzheimer's disease (AD) pathogenesis and mixed dementia phenotypes. While amyloid and tau pathologies have dominated AD research, accumulating evidence suggests vascular dysfunction may precede and accelerate neurodegeneration. This comprehensive clinical study aims to validate the mechanistic role of CSVD in AD progression and characterize mixed pathology presentations combining vascular and neurodegenerative features. The study employs a longitudinal cohort design recruiting participants across the cognitive spectrum, from cognitively normal elderly to mild cognitive impairment and dementia patients. Advanced neuroimaging will quantify CSVD burden using white matter hyperintensities, lacunes, microbleeds, and perivascular spaces on high-resolution MRI. Simultaneous assessment of AD biomarkers through cerebrospinal fluid analysis and PET imaging will enable correlation of vascular pathology with amyloid and tau accumulation. Cognitive assessments will track decline patterns specific to vascular versus AD pathology. The innovation lies in integrating multimodal biomarkers to dissect the temporal relationship between vascular dysfunction and classic AD pathology, potentially identifying distinct endophenotypes of mixed dementia. This research addresses a critical knowledge gap in dementia classification and could revolutionize therapeutic approaches by validating vascular targets for intervention, particularly in patients with mixed pathology who may respond differently to current AD treatments.
This experiment directly tests predictions arising from the following hypotheses:
Retinal Vascular Microcirculation Rescue
Pericyte Contractility Reset via Selective PDGFR-β Agonism
Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation
SASP-Driven Aquaporin-4 Dysregulation
Aquaporin-4 Polarization Rescue
Experimental Protocol
Phase 1 (Months 1-6): Recruit 300 participants aged 65-85 across three cognitive groups: cognitively normal (n=100), mild cognitive impairment (n=100), and mild-moderate dementia (n=100). Screen participants using comprehensive neuropsychological batteries including MMSE, MoCA, and domain-specific tests. Phase 2 (Months 7-18): Conduct baseline multimodal neuroimaging including 3T MRI with FLAIR, T2*, and DTI sequences to quantify CSVD markers, plus amyloid and tau PET imaging using 18F-florbetapir and 18F-flortaucipir tracers. Collect cerebrospinal fluid via lumbar puncture for Aβ42, total tau, and p-tau181 quantification using ELISA. Assess vascular risk factors including blood pressure monitoring, lipid profiles, and diabetes status. Phase 3 (Months 19-42): Perform longitudinal follow-up at 6-month intervals with cognitive assessments and annual neuroimaging. Employ mixed-effects modeling to analyze relationships between CSVD burden (Fazekas scale, lacune count) and biomarker trajectories. Phase 4 (Months 43-48): Statistical analysis using regression models to determine independent contributions of vascular versus AD pathology to cognitive decline, controlling for age, education, and APOE genotype. Validate findings using machine learning approaches for pathology classification.
Expected Outcomes
1. CSVD burden will independently predict cognitive decline with hazard ratio >1.5 (p<0.01) after controlling for amyloid and tau pathology
2. Mixed pathology patients (high CSVD + positive AD biomarkers) will show 30-40% faster decline on executive function tests compared to pure AD pathology
3. White matter hyperintensity volume will correlate negatively with CSF Aβ42 levels (r=-0.3 to -0.5, p<0.001) suggesting synergistic pathological processes
4. Participants with severe CSVD will demonstrate distinct cognitive phenotypes with greater impairment in processing speed and executive function versus memory
5. Longitudinal tau PET will show accelerated accumulation (20-25% higher SUVR slope) in regions with concurrent vascular pathology
6. Machine learning models incorporating vascular biomarkers will achieve >85% accuracy in predicting mixed versus pure AD pathology classification
Success Criteria
• Demonstrate statistically significant independent association between CSVD burden and cognitive decline (p<0.05) in multivariable models
• Achieve >80% participant retention through 24-month follow-up period with complete biomarker data
• Identify at least 3 distinct neuroimaging signatures of mixed pathology with >70% classification accuracy
• Establish validated CSVD severity staging system with inter-rater reliability >0.85 for clinical implementation
• Publish primary findings in high-impact journal (IF>10) demonstrating clinical relevance of vascular contributions to AD
• Generate preliminary data supporting at least 2 follow-up grant applications for vascular-targeted therapeutic trials
TARGET GENE
CSVD
MODEL SYSTEM
human
ESTIMATED COST
$5,460,000
TIMELINE
45 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate Vascular Contributions to Alzheimer Disease and Mixed Pathology
Phase 1 (Months 1-6): Recruit 300 participants aged 65-85 across three cognitive groups: cognitively normal (n=100), mild cognitive impairment (n=100), and mild-moderate dementia (n=100). Screen participants using comprehensive neuropsychological batteries including MMSE, MoCA, and domain-specific tests. Phase 2 (Months 7-18): Conduct baseline multimodal neuroimaging including 3T MRI with FLAIR, T2*, and DTI sequences to quantify CSVD markers, plus amyloid and tau PET imaging using 18F-florbetapir and 18F-flortaucipir tracers. Collect cerebrospinal fluid via lumbar puncture for Aβ42, total tau, and p-tau181 quantification using ELISA. Assess vascular risk factors including blood pressure monitoring, lipid profiles, and diabetes status.
...
Phase 1 (Months 1-6): Recruit 300 participants aged 65-85 across three cognitive groups: cognitively normal (n=100), mild cognitive impairment (n=100), and mild-moderate dementia (n=100). Screen participants using comprehensive neuropsychological batteries including MMSE, MoCA, and domain-specific tests. Phase 2 (Months 7-18): Conduct baseline multimodal neuroimaging including 3T MRI with FLAIR, T2*, and DTI sequences to quantify CSVD markers, plus amyloid and tau PET imaging using 18F-florbetapir and 18F-flortaucipir tracers. Collect cerebrospinal fluid via lumbar puncture for Aβ42, total tau, and p-tau181 quantification using ELISA. Assess vascular risk factors including blood pressure monitoring, lipid profiles, and diabetes status. Phase 3 (Months 19-42): Perform longitudinal follow-up at 6-month intervals with cognitive assessments and annual neuroimaging. Employ mixed-effects modeling to analyze relationships between CSVD burden (Fazekas scale, lacune count) and biomarker trajectories. Phase 4 (Months 43-48): Statistical analysis using regression models to determine independent contributions of vascular versus AD pathology to cognitive decline, controlling for age, education, and APOE genotype. Validate findings using machine learning approaches for pathology classification.
Expected Outcomes
1. CSVD burden will independently predict cognitive decline with hazard ratio >1.5 (p<0.01) after controlling for amyloid and tau pathology
2. Mixed pathology patients (high CSVD + positive AD biomarkers) will show 30-40% faster decline on executive function tests compared to pure AD pathology
3. White matter hyperintensity volume will correlate negatively with CSF Aβ42 levels (r=-0.3 to -0.5, p<0.001) suggesting synergistic pathological processes
4.
...
1. CSVD burden will independently predict cognitive decline with hazard ratio >1.5 (p<0.01) after controlling for amyloid and tau pathology
2. Mixed pathology patients (high CSVD + positive AD biomarkers) will show 30-40% faster decline on executive function tests compared to pure AD pathology
3. White matter hyperintensity volume will correlate negatively with CSF Aβ42 levels (r=-0.3 to -0.5, p<0.001) suggesting synergistic pathological processes
4. Participants with severe CSVD will demonstrate distinct cognitive phenotypes with greater impairment in processing speed and executive function versus memory
5. Longitudinal tau PET will show accelerated accumulation (20-25% higher SUVR slope) in regions with concurrent vascular pathology
6. Machine learning models incorporating vascular biomarkers will achieve >85% accuracy in predicting mixed versus pure AD pathology classification
Success Criteria
• Demonstrate statistically significant independent association between CSVD burden and cognitive decline (p<0.05) in multivariable models
• Achieve >80% participant retention through 24-month follow-up period with complete biomarker data
• Identify at least 3 distinct neuroimaging signatures of mixed pathology with >70% classification accuracy
• Establish validated CSVD severity staging system with inter-rater reliability >0.85 for clinical implementation
• Publish primary findings in high-impact journal (IF>10) demonstrating clinical relevance of vascular contributions to AD
• Gen
...
• Demonstrate statistically significant independent association between CSVD burden and cognitive decline (p<0.05) in multivariable models
• Achieve >80% participant retention through 24-month follow-up period with complete biomarker data
• Identify at least 3 distinct neuroimaging signatures of mixed pathology with >70% classification accuracy
• Establish validated CSVD severity staging system with inter-rater reliability >0.85 for clinical implementation
• Publish primary findings in high-impact journal (IF>10) demonstrating clinical relevance of vascular contributions to AD
• Generate preliminary data supporting at least 2 follow-up grant applications for vascular-targeted therapeutic trials